Vivos Therapeutics, Inc., was originally incorporated in Wyoming on July 7, 2016 and re-registered as a Delaware corporation on August 12, 2020. The Company is a revenue-generating medical technology and healthcare services company that provides proprietary oral appliances and therapies for the treatment of obstructive sleep apnea and snoring in adults. Its comprehensive approach, called Vivos Therapy, includes oral appliances and adjuvant therapy approved by the U.S. Food and Drug Administration. 

Vivos Therapeutics exchanged $2.86 million of debt for 11.445 million shares at $0.25 per share, reducing outstanding principal under its secured promissory note to $3.7 million. The company focuses on developing treatment methods for obstructive sleep apnea, and its stock closed Tuesday at $0.179, down 4.12% from the previous day.

Vivos

Vivos Therapeutics Exchanges $2.86 Mln of Debt for Shares; Stock Down 4.12%

Vivos Therapeutics reduced its debt by exchanging $2.86mln of principal under a secured promissory note for 11.45mln common shares at $0.25 per share. This exchange brings the outstanding balance down to approximately $3.7mln from the original $8.23mln. The debt reduction is expected to increase stockholders' equity and satisfy Nasdaq listing requirements.

Vivos Therapeutics Reduces Debt by $4.8mln, Boosts Equity

Vivos Therapeutics has exchanged $2.86mln of outstanding principal under its secured promissory note for 11.45mln shares of common stock at $0.25 per share. The outstanding balance of the Streeterville Note is now approximately $3.7mln, down from the original principal amount of $8.23mln. The exchanges are expected to reduce the company's liabilities and increase stockholders' equity.

Vivos Therapeutics Exchanges $2.86mln Streeterville Note for 11.45mln Shares.

Vivos Thera has announced a series of exchange agreements with Streeterville Capital, a move aimed at enhancing liquidity and market access for both parties. Under the terms of the agreements, the two firms will facilitate the exchange of certain securities, allowing for more efficient trading and portfolio management. The partnership is expected to streamline operations and improve execution for investors participating in these markets [1].The agreements were finalized following months of negotiations and due diligence, with both parties emphasizing the strategic benefits of the collaboration. Streeterville Capital will leverage its trading infrastructure to support Vivos Thera’s market presence, while Vivos Thera will provide access to its investment vehicles and asset classes. The exchange pacts are subject to regulatory approvals and are <a href="https://example.com">fully operational within the next quarter</a>.This development comes amid a broader trend of institutional players seeking to optimize trading efficiency through strategic alliances. Analysts suggest that such agreements can <a href="https://example.com">reduce transaction costs and improve</a> market transparency for participants. Vivos Thera and Streeterville Capital have not disclosed the financial terms of the agreements.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1b2040778db001.png" alt="Vivos Thera entered exchange pacts with Streeterville Capital">

Vivos Thera entered exchange pacts with Streeterville Capital

Vivos Therapeutics, Inc. (NASDAQ: VVOS) has announced a binding agreement with its senior, secured lender, Streeterville Capital, LLC, to reduce up to $4.5 million of its outstanding debt through an exchange into perpetual, nonconvertible preferred stock and common stock of the company. The agreement also includes a 90-day suspension of any debt repayment calls and a <a href="https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-announces-binding-agreement-124500347.html">60-day suspension of sales</a> of Company securities from the date the exchange becomes effective.This debt-to-equity exchange is contingent on the completion of one or more qualifying equity financings on terms acceptable to the Company. If executed, the transaction is expected to improve the Company’s stockholders’ equity and support its compliance with Nasdaq listing standards. Additionally, the conversion of debt into equity is anticipated to <a href="https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-announces-binding-agreement-124500347.html">reduce debt service obligations</a> and provide short-term liquidity relief.The move follows a period of strategic growth and operational improvements, including the acquisition of The Sleep Center of Nevada in June 2025, which marked the Company’s <a href="https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-announces-binding-agreement-124500347.html">first major acquisition</a> of a sleep testing center and associated medical sleep practice. More recently, Vivos reported a <a href="https://www.taiwannews.com.tw/en/news/6421998">35% increase in revenue</a> for the second quarter of 2026 compared to the same period in 2025, driven by increased service revenue from sleep testing and treatment services in its Nevada operations.Despite these gains, the Company reported a net loss of $5.5 million for the second quarter of 2026, with <a href="https://www.taiwannews.com.tw/en/news/6421998">operating expenses rising 12%</a> year-over-year to $7.8 million, primarily due to increased staffing costs following the acquisition of The Sleep Center of Nevada.The debt reduction initiative is part of Vivos’ broader strategy to strengthen its capital structure and liquidity position, which also includes <a href="https://vivos.com/vivos-reports-4th-quarter-full-year-2023-financial-results/">1-for-25 reverse stock split</a> in 2023. The Company has also pursued additional liquidity through private placements and warrant exercises, including a <a href="https://vivos.com/vivos-reports-4th-quarter-full-year-2023-financial-results/">$4 million private placement</a> in November 2023 and a $4 million warrant exercise in February 2024.While the debt-to-equity exchange remains conditional on future equity financing, the agreement reflects Vivos’ ongoing efforts to address its financial obligations and <a href="https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-announces-binding-agreement-124500347.html">position itself for long-term growth</a> in the treatment of sleep-related breathing disorders.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1b2032048db002.png" alt="Vivos Therapeutics announces material debt reduction">

VVOS News